Crinetics Pharmaceuticals (CRNX)

Company Profile

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Company profile

Ticker

CRNX

Exchange

NASDAQ

Website

www.crinetics.com/

CEO

R. Scott Struthers

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

0001658247

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CRNX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

13 Sep 23

424B5

Prospectus supplement for primary offering

13 Sep 23

424B5

Prospectus supplement for primary offering

11 Sep 23

8-K

Regulation FD Disclosure

8 Aug 23

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

8 Aug 23

8-K

Submission of Matters to a Vote of Security Holders

9 May 23

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

4 May 23

ARS

2022 FY

Annual report to shareholders

27 Apr 23

Transcripts

CRNX

Earnings call transcript

2020 Q4

31 Mar 21

Latest ownership filings

View all

SC 13G

Point72 Asset Management, L.P.

18 Sep 23

Richard Scott Struthers

16 Aug 23

Richard Scott Struthers

13 Jul 23

144

Notice of proposed sale of securities

13 Jul 23

144

Notice of proposed sale of securities

12 Jul 23

144

Notice of proposed sale of securities

11 Jul 23

Marc Wilson

21 Jun 23

Richard Scott Struthers

21 Jun 23

Coelho Rogerio Vivaldi

21 Jun 23

Caren Deardorf

21 Jun 23

Financial summary

Financial statements Chart CRNX financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	40.85 mm	40.85 mm	40.85 mm	40.85 mm	40.85 mm	40.85 mm
Cash burn (monthly)	547.00 k	1.83 mm	17.67 mm	16.00 mm	15.25 mm	13.34 mm
Cash used (since last report)	1.65 mm	5.51 mm	53.21 mm	48.19 mm	45.92 mm	40.20 mm
Cash remaining	39.21 mm	35.35 mm	-12.35 mm	-7.34 mm	-5.07 mm	657.76 k
Runway (months of cash)	71.7	19.3	-0.7	-0.5	-0.3	0.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

CRNX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	141	128	+10.2%
Opened positions	28	18	+55.6%
Closed positions	15	15	–
Increased positions	55	58	-5.2%
Reduced positions	33	27	+22.2%

13F shares	Current	Prev Q	Change
Total value	944.36 bn	850.33 bn	+11.1%
Total shares	58.35 mm	59.27 mm	-1.6%
Total puts	21.10 k	100.00	+21000.0%
Total calls	1.10 k	22.60 k	-95.1%
Total put/call ratio	19.2	0.0	+433409.1%

Largest owners	Shares	Value	Change
Driehaus Capital Management	5.30 mm	$95.47 bn	+0.2%
BLK Blackrock	4.60 mm	$82.90 bn	+16.3%
Orbimed Advisors	3.95 mm	$71.19 bn	0.0%
Wellington Management	3.60 mm	$64.90 bn	-0.9%
Biotechnology Value Fund L P	2.74 mm	$0.00	0.0%
Vanguard	2.73 mm	$49.24 bn	+1.5%
Bain Capital Life Sciences Investors	2.31 mm	$41.55 bn	0.0%
STT State Street	2.24 mm	$40.32 bn	+0.9%
Perceptive Advisors	1.95 mm	$35.08 bn	-45.2%
First Light Asset Management	1.56 mm	$28.06 bn	-3.8%

Largest transactions	Shares	Bought/sold	Change
BVF	0.00	-2.74 mm	EXIT
Perceptive Advisors	1.95 mm	-1.61 mm	-45.2%
T. Rowe Price	1.43 mm	+1.39 mm	+3319.8%
Braidwell	650.31 k	-1.37 mm	-67.8%
BLK Blackrock	4.60 mm	+644.13 k	+16.3%
Ikarian Capital	475.00 k	+475.00 k	NEW
Jennison Associates	461.50 k	+461.50 k	NEW
Paradigm Biocapital Advisors	1.40 mm	+261.22 k	+23.0%
Point72 Asset Management	0.00	-226.40 k	EXIT
Adage Capital Partners GP, L.L.C.	225.00 k	+225.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Aug 23	Struthers Richard Scott	Common Stock	Option exercise	Acquire M	No	No	1.91	10,000	19.10 k	135,522
14 Aug 23	Struthers Richard Scott	Incentve stock option Common Stock	Option exercise	Dispose M	No	No	1.91	10,000	19.10 k	151,270
13 Jul 23	Struthers Richard Scott	Common Stock	Sell	Dispose S	Yes	No	20.35	14,157	288.09 k	630,805
12 Jul 23	Struthers Richard Scott	Common Stock	Sell	Dispose S	Yes	No	20.17	11,459	231.13 k	644,962
11 Jul 23	Struthers Richard Scott	Common Stock	Sell	Dispose S	Yes	No	20.14	24,384	491.09 k	656,421
20 Jun 23	Marc Wilson	Common Stock	Sell	Dispose S	No	No	19.97	20,000	399.40 k	95,158
20 Jun 23	Marc Wilson	Common Stock	Option exercise	Acquire M	No	No	9.28	20,000	185.60 k	115,158
20 Jun 23	Marc Wilson	Common Stock	Sell	Dispose S	No	No	19.96	10,922	218.00 k	95,158
20 Jun 23	Marc Wilson	NQSO Common Stock	Option exercise	Dispose M	No	No	9.28	20,000	185.60 k	71,185
16 Jun 23	Fust Matthew K	Common Stock	Grant	Acquire A	No	No	0	6,000	0.00	18,536